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A B S T R A C T
Rationale and objective: Central and South America comprise one of the areas characterized by high
incidence rates for head and neck cancer. We describe the geographical and temporal trends in incidence
and mortality of head and neck cancers in the Central and South American region in order to identify
opportunities for intervention on the major identiﬁed risk factors: tobacco control, alcohol use and viral
infections.
Methods: We obtained regional- and national-level incidence data from 48 population-based cancer
registries in 13 countries and cancer deaths from the WHO mortality database for 18 countries. Age-
standardized incidence (ASR) and mortality (ASMR) rates per 100,000 person-years were estimated.
Results: Brazil had the highest incidence rates for oral and pharyngeal cancer in the region for both sexes,
followed by Cuba, Uruguay and Argentina. Cuba had the highest incidence and mortality rates of
laryngeal cancer in the region for males and females. Overall, males had rates about four times higher
than those in females. Most countries in the region have implemented WHO recommendations for both
tobacco and alcohol public policy control.
Conclusion: Head and neck squamous-cell cancer (HNSCC) incidence and mortality rates in the Central
and South America region vary considerably across countries, with Brazil, Cuba, French Guyana, Uruguay
and Argentina experiencing the highest rates in the region. Males carry most of the HNSCC burden.
Improvement and implementation of comprehensive tobacco and alcohol control policies as well as the
monitoring of these factors are fundamental to prevention of head and neck cancers in the region.
ã 2015 International Agency for Research on Cancer; Licensee Elsevier Ltd. This is an open access article
under the CC BY-NC-ND IGO 3.0 license (https://creativecommons.org/licenses/by-nc-nd/3.0/igo/).
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Head and neck cancers comprise a heterogeneous group of
cancers which include those of the lip, oral cavity, nasopharynx,
oropharynx, hypopharynx, pharynx, and larynx. Squamous-cell
carcinomas (SCCs) account for 90% of malignant tumors of the$ This is an Open Access article published under the CC BY NC ND 3.0 IGO license
which permits users to download and share the article for non-commercial
purposes, so long as the article is reproduced in the whole without changes, and
provided the original source is properly cited. This article shall not be used or
reproduced in association with the promotion of commercial products, services or
any entity. There should be no suggestion that IARC endorses any speciﬁc
organisation, products or services. The use of the IARC logo is not permitted. This
notice should be preserved along with the article’s original URL.
* Corresponding author at: International Agency for Research on Cancer,
Section of Genetics, 150 Cours Albert Thomas 69372 Lyon Cedex 08, France.
E-mail address: perdomos@fellows.iarc.fr (S. Perdomo).
http://dx.doi.org/10.1016/j.canep.2016.03.012
1877-7821/ã 2015 International Agency for Research on Cancer; Licensee Elsevier Ltd
creativecommons.org/licenses/by-nc-nd/3.0/igo/).head and neck and develop in the mucosal linings of the upper
aerodigestive tract. Collectively, these cancers are the seventh
most common malignancy diagnosed worldwide. In 2012, almost
700,000 new head and neck cancer cases were estimated to occur
worldwide, with 6.5% (45,403) of them occurring in the Central and
South American region (including Cuba). Head and neck cancers
are also the seventh most common cause of death in the world,
accounting for approximately 375,000 cancer deaths; 5.8% (21,762)
of those deaths occur in Central and South America. It is expected
that by the year 2030, the global burden of head and neck cancers
will increase by approximately 34% (1,031,479 new cases and
576,563 deaths), while in Central and South America the burden is
expected to increase by almost 7% (72,985 new cases and
37,909 deaths) [1].
Central and South America are regions characterized by high
incidence rates for head and neck cancer [2]; however, the rates
among countries of the region vary widely. There is a sex disparity. This is an open access article under the CC BY-NC-ND IGO 3.0 license (https://
S44 S. Perdomo et al. / Cancer Epidemiology 44S (2016) S43–S52in head and neck cancers, with males carrying more than 72% of
burden in the region (31,758 new cases and 17,160 deaths). Cancers
of the oral cavity and larynx represent the ﬁfth and seventh more
common cancers in men in Brazil [3]. The Brazilian male
population has the highest risk in the world for cancer of mouth,
after those in France and India [4]. It has been reported that
Brazilian and Cuban men had higher mortality rates from head and
neck cancers than men in the United States and Canada [5].
Although a slow decline in mortality rates from head and neck
cancers has been described among Argentinean and Chilean men,
in Cuba mortality rates from these malignancies are still on the rise
among men and women [5]. These results are of particular concern
since incidence estimates for most countries in the Central and
South American region are still lacking.
Cigarette smoking and alcohol use are the main factors
consistently associated with the incidence and mortality of head
and neck cancers [6,7]. Human papillomavirus (HPV) is associated
with head and neck squamous-cell cancer (HNSCC) and is strongly
related to oropharyngeal cancer [8]. Recent studies revealed that
HPV-positive tumors constitute approximately 25% of all HNSCCs
and that the prevalence is signiﬁcantly higher in cancer of the
oropharynx (35.6%, range 11–100%) than in the oral cavity (23.5%,
range 40–80%) or larynx (24.0%, range 0–100%); HPV16, a high-risk
subtype, is the predominant genotype found [9,10].
This paper aims to describe the geographical and temporal
trends in incidence and mortality of head and neck cancers in the
Central and South American region in order to identify oppor-
tunities for intervention, with particular focus on the major
identiﬁed risk factors related to this malignancy: tobacco control,
alcohol use and viral infections. Description of burden patterns has
been done in two separate groups: cancers of the lip, oral cavity
and pharynx, and cancer of the larynx.
2. Methods
The data sources and methods are described in detail in an
earlier article in this issue [60]. In brief, we obtained regional- and
national-level incidence data from 48 population-based cancer
registries in 13 countries, and cancer deaths from the World
Health Organization mortality database for 18 countries. We
estimated age-standardized incidence rates (ASRs) and mortality
rates (ASMRs) per 100,000 person-years using the direct method
and the World standard population [11,12]. We estimated national
ASRs by aggregating the data from the available cancer registries
using a weighted average of local rates. To describe incidence and
mortality time trends, we calculated the estimated annual
percentage change (EAPC) using the method proposed by Esteve
et al. [13]. Trends in incidence and mortality and EAPCs were
estimated for four countries (Table 1). All of the EAPCs were
tested for equality to zero by using the corresponding standard
errors. We considered EAPCs statistically signiﬁcant if the P-
value  0.05. We conducted the data analysis in Stata version 12.1
(StataCorp) [14].Table 1
Countries included in the analysis of time trends.
Country Name of registries included 
Argentina Bahia Blanca 
Brazil Aracaju, Fortaleza, Goiania, Sao Paulo 
Chile Valdivia 
Costa Rica National registry 3. Results
3.1. Lip, oral cavity and pharynx cancer
3.1.1. Age-standardized incidence and mortality rates
The incidence and mortality of oral cavity and pharyngeal
cancer in Central and South America vary widely. Males generally
had higher incidence and mortality rates (per 100,000) of oral
cavity and pharyngeal cancer than females (male-to-female ratios
ranging from 4:1 to 2:1); the lowest sex ratio differences are
found in Ecuador (0.95:1), Peru (1.07: 1) and Bolivia (1.14: 1)
(Table 2).
Brazil had the highest incidence rates in the region for both
sexes (19.7 for males and 5.0 for females). In Central America, Cuba
had the highest age-standardized incidence rates (per 100,000) in
males (10.0) and females (3.6), while the lowest rates were in El
Salvador and Mexico (<2.7). In South America – apart from Brazil –
French Guyana and Uruguay had the highest incidence rates in
males (16.9 and 10.1, respectively), whereas Bolivia and Ecuador
presented the lowest rates (<2.0). The regional female incidence
rates were low (<2.0) except for those in Brazil (5.0), Cuba (3.6) and
Colombia (3.0).
Similar geographical and sex differences were observed for oral
and pharyngeal cancer mortality rates (per 100,000). In Central
America, Cuba had the highest mortality rate among both males
(5.8) and females (1.7), while El Salvador and Mexico had the
lowest rates (1.4–1.8 among males and 0.6–0.7among females,
respectively). In South America the highest mortality rates in males
occurred in Brazil (5.9) and Uruguay (5.7) and in females in Brazil
(1.2) and Colombia (1.0), while the lowest were in Peru (0.7 in
males 0.6 in females) and Ecuador (1.0 in males 0.6 in females).
3.1.2. Time trends
Trends in oral cavity and pharyngeal cancer incidence and
mortality in Argentina (1998–2007), Brazil (1997–2006), Chile
(1998–2008) and Costa Rica (1985–2007) are shown in Fig. 1. The
secular trend in oral cavity and pharyngeal cancer in both males
and females in Argentina declined over the 10 years (7% and 5%
per annum respectively, P > 0.05) while in Brazil rates remained
stable. In Costa Rica, incidence rates among males and females
steadily declined between 1985 and 1995 and stabilized thereafter.
In Chile, females showed a steady increase in incidence, while in
males the pattern was unclear because of large ﬂuctuations in the
data, probably because of the small number of cases. Mortality
rates in both sexes followed the incidence pattern across countries
except for males in Costa Rica, where mortality seem to increase
slightly after the year 2000, and females in Chile where mortality
showed a slight decrease after the year 2005.
The estimated annual percentage change in incidence and
mortality rates for oral cavity and pharyngeal cancer over the most
recent 10-year period revealed negligible or small changes in the
rates in Brazil, Chile and Costa Rica, with larger declines in
Argentina (2% per annum for males and 1% for females);
however, none of the estimates was statistically signiﬁcant (Fig. 2).Period % of the population covered
1993–2007 0.8
1997–2006 8.0
1993–2008 2.2
1985–2007 100.0
Table 2
Age-standardized incidence and mortality rates (per 100,000) from lip, oral cavity, and pharynx cancers (C00-14) in Central and South America, all ages.
Incidence Mortality
Country Period Sex Cases Crude rate ASR (W) Cum. rate MV% Rankb Deaths Crude rate ASR (W) Cum. rate Rankb
Argentinaa 2003–2007 Females 338 2.6 2.2 0.24 89 20 1098 1.1 0.7 0.08 18
2003–2007 Males 763 6.2 6.4 0.76 88 12 3087 3.3 3.0 0.37 13
Belizec 2003–2007 Females 1 0.1 0.3 0.05 17
2003–2007 Males 11 1.6 2.5 0.22 9
Boliviaa 2011 Females 18 1.3 1.4 0.18 100 10
2011 Males 19 1.4 1.6 0.17 100 6
Brazila 2003–2007 Females 3077 5.0 5.0 0.53 80 11 5560 1.2 1.2 0.12 13
2003–2007 Males 8684 15.6 19.7 2.33 86 5 22947 5.0 5.9 0.70 5
Chilea 2003–2007 Females 41 1.8 1.6 0.16 83 21 291 0.7 0.5 0.05 20
2003–2007 Males 72 3.1 3.4 0.40 88 15 678 1.7 1.7 0.21 15
Colombiaa 2003–2007 Females 325 3.2 3.0 0.33 93 15 1001 0.9 1.0 0.11 14
2003–2007 Males 419 4.6 5.2 0.62 94 10 1483 1.4 2.0 0.23 12
Costa Rica 2003–2007 Females 215 2.0 2.1 0.22 94 18 84 0.8 0.8 0.08 16
2003–2007 Males 459 4.2 5.0 0.56 93 10 223 2.0 2.4 0.28 10
1985–1989 Females 144 2.1 2.8 0.31 90 13 57 0.8 1.0 0.11 9
1985–1989 Males 311 4.3 6.6 0.76 95 6 142 2.0 2.9 0.34 8
Cubaa 2004–2007 Females 93 5.8 3.6 0.42 91 13 621 2.8 1.7 0.18 13
2004–2007 Males 242 14.8 10.0 1.13 89 5 1753 7.7 5.8 0.65 6
Ecuadora 2003–2007 Females 94 1.8 1.9 0.21 95 19 175 0.5 0.6 0.06 15
2003–2007 Males 70 1.5 1.8 0.18 96 19 261 0.8 1.0 0.10 12
El Salvador 1999–2003 Females 111 0.8 0.8 0.09 95 13 83 0.5 0.6 0.07 13
1999–2003 Males 142 1.1 1.4 0.17 95 9 143 1.0 1.4 0.17 5
French Guyanaa 2003–2008 Females 15 3.0 4.2 0.56 100 12
2003–2008 Males 57 11.5 16.9 2.42 91 3
Guatemala 2003–2007 Females 254 0.8 1.2 0.12 10
2003–2007 Males 394 1.3 2.1 0.20 7
Mexicoa 2006–2010 Females 213 1.2 1.3 0.14 100 17 1541 0.5 0.7 0.06 18
2006–2010 Males 357 2.1 2.6 0.29 100 12 3162 1.1 1.8 0.16 14
Nicaragua 2003–2007 Females 43 0.3 0.4 0.04 14
2003–2007 Males 108 0.8 1.4 0.14 9
Panama 2003–2007 Females 78 1.0 1.0 0.08 14
2003–2007 Males 150 1.8 2.2 0.25 9
Paraguay 2003–2007 Females 73 0.5 0.7 0.07 14
2003–2007 Males 278 1.9 2.8 0.33 6
Perub 2001–2005 Females 271 2.8 2.8 0.30 87 16 334 0.5 0.6 0.06 15
2001–2005 Males 255 2.8 3.0 0.34 93 15 356 0.5 0.7 0.07 14
Suriname 2003–2007 Females 7 0.6 0.5 0.06 14
2003–2007 Males 17 1.4 1.8 0.23 10
Uruguay 2005–2007 Females 202 3.9 2.5 0.26 90 19 96 1.9 0.9 0.09 16
2005–2007 Males 606 12.6 10.1 1.22 87 9 342 7.1 5.7 0.71 8
Venezuela 2003–2007 Females 558 0.8 1.0 0.10 15
2003–2007 Males 1125 1.7 2.3 0.28 9
ASR (W), age-standardized (World population) rate per 100,000; Cum, cumulative; MV, microscopic veriﬁcation.
a Rank based on highest ASR excluding: All sites but C44 and All sites.
b Incidence rates were estimated using data from regional cancer registries.
c Mortality rates based on a small number of cases.
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3.2.1. Age-standardized incidence and mortality rates
Males had noticeably higher incidence and mortality rates (per
100,000) of laryngeal cancer than females (male-to-female ratios
ranging from 4:1 to 9:1, except in Bolivia where the ratio for
incidence is the lowest at 1.5:1) (Table 3). Cuba had the highest
incidence and mortality rates than any country in the region, for
both males (13.0 and 7.8, respectively) and females (1.4 and 1.2,
respectively). However, the incidence rate is likely to be under-
estimated because the numbers of new cancer cases were obtained
only for the population of Villa Clara; thus the true national
incidence is expected to be even higher.
Brazilian and Uruguayan males also have noticeably higher
incidence rates of cancer of the larynx (9.7 and 7.2, respectively). In
contrast, Ecuadorian and Peruvian males had the lowest incidence
rates of larynx cancer observed in the region (1.2 and 1.7,
respectively), excluding the rates from El Salvador and Bolivia
because of the poor coverage of the Salvadorian cancer registry and
the recent activities from the Bolivian registry.3.2.2. Time trends
Trends in laryngeal cancer incidence and mortality in
Argentina, Brazil, Chile and Costa Rica are shown in Fig. 3. Overall,
incidence and mortality rates among males in Costa Rica
(1985–2007) were stable over the ﬁrst 20 years; however, they
slowly declined in the most recent 10-year period on average by
2% per annum, P > 0.05 (Figs. 3 and 4). Among males in Argentina
(1998–2007) and Chile (1997–2008) both the incidence and
mortality of laryngeal cancers declined after the year 2002; the
estimated annual percentage change of incidence and mortality in
males during the observation period was 6.0 and 2.7 for
Argentina and 4.1 and 3.8 for Chile. In Brazil (1997–2006) both
incidence and mortality among males declined until the mid-
2000s but seem to be on the rise thereafter (Figs. 3 and 4).
Among females in these countries, the incidence and mortality
time trend patterns are less clear. Both incidence and mortality
rates in Brazilian females show the most stable trends over time.
Longer time series are needed to examine whether there is a real
decline in the rates or merely ﬂuctuation of the data due to small
numbers.
Fig. 1. Trends in cancer incidence and mortality by country and sex, all ages.
S46 S. Perdomo et al. / Cancer Epidemiology 44S (2016) S43–S523.3. Tobacco and alcohol preventive measures
Tobacco smoking and alcohol consumption are preventable
factors associated with an increased risk of head and neck cancers.
It has been estimated that 45.7% [30.1, 57.7] of the head and neck
cancer cases that occurred in the IARC–Latin America Multicentre
study were due to the synergistic effect of smoking and alcohol use,Fig. 2. Estimated annual percentage change in age-standardwhile 4.3% [0.2, 5.6] were attributable to alcohol alone and 32.9%
[26.3, 40.2] to tobacco alone [15]. It has also been shown that
quitting tobacco smoking and alcohol reduces the risk of
developing HNSCC. The International Head and Neck Cancer
Epidemiology (INHANCE) consortium reported that smoking
cessation for 1–4 years was associated with a 30% [0.61, 0.81]
lower risk of head and neck cancers than that in current smokers;ized incidence and mortality rates per 100,000 by sex.
Table 3
Age-standardized incidence and mortality rates (per 100,000) from laryngeal cancer (C32) in Central and South America, all ages.
Incidence Mortality
Country Period Sex Cases Crude rate ASR (W) Cum. rate MV% Rankb Deaths Crude rate ASR (W) Cum. Rate Rankb
Argentinaa 2003–2007 Females 89 0.7 0.6 0.07 76 24 480 0.5 0.3 0.04 21
2003–2007 Males 705 5.7 5.9 0.74 82 13 4008 4.2 3.9 0.49 11
Belizec 2003–2007 Females 1 0.1 0.1 0.01 22
2003–2007 Males 8 1.2 1.8 0.14 10
Boliviaa 2011 Females 2 0.1 0.2 0.02 100 23
2011 Males 3 0.2 0.3 0.04 100 22
Brazila 2003–2007 Females 739 1.2 1.3 0.15 82 24 1842 0.4 0.4 0.05 19
2003–2007 Males 4079 7.3 9.7 1.20 83 9 13694 3.0 3.6 0.45 9
Chilea 2003–2007 Females 17 0.8 0.7 0.10 82 24 86 0.2 0.2 0.02 22
2003–2007 Males 57 2.4 2.6 0.34 82 18 555 1.4 1.4 0.17 16
Colombiaa 2003–2007 Females 57 0.6 0.5 0.06 86 25 482 0.4 0.5 0.05 20
2003–2007 Males 288 3.2 3.8 0.47 89 12 1601 1.5 2.2 0.25 11
Costa Rica 2003–2007 Females 25 0.2 0.3 0.03 84 25 16 0.2 0.2 0.02 22
2003–2007 Males 263 2.4 3.0 0.36 90 15 149 1.4 1.6 0.18 14
1985–1989 Females 27 0.4 0.6 0.06 81 23 26 0.4 0.5 0.05 12
1985–1989 Males 155 2.2 3.5 0.46 88 12 124 1.7 2.5 0.29 9
Cubaa 2004–2007 Females 38 2.4 1.4 0.15 84 19 393 1.8 1.2 0.14 18
2004–2007 Males 315 19.2 13.0 1.68 90 4 2380 10.5 7.8 0.91 4
Ecuadora 2003–2007 Females 12 0.2 0.3 0.03 75 25 43 0.1 0.1 0.02 21
2003–2007 Males 46 1.0 1.2 0.14 87 21 182 0.5 0.7 0.07 14
El Salvadora 1999–2003 Females 26 0.2 0.2 0.03 88 19 25 0.2 0.2 0.03 23
1999–2003 Males 116 0.9 1.1 0.14 90 11 94 0.7 0.9 0.10 9
French Guyanaa 2003–2008 Females 0 0.0 0.0 0.00 26
2003–2008 Males 13 2.6 4.4 0.58 100 15
Guatemala 2003–2007 Females 45 0.1 0.2 0.02 19
2003–2007 Males 146 0.5 0.8 0.09 11
Mexicoa 2006–2010 Females 45 0.3 0.3 0.04 100 22 536 0.2 0.3 0.02 22
2006–2010 Males 306 1.8 2.3 0.28 100 13 3460 1.2 2.1 0.18 11
Nicaragua 2003–2007 Females 16 0.1 0.2 0.03 19
2003–2007 Males 73 0.5 0.9 0.09 12
Panama 2003–2007 Females 11 0.1 0.1 0.01 21
2003–2007 Males 111 1.4 1.6 0.18 13
Paraguay 2003–2007 Females 14 0.1 0.1 0.01 20
2003–2007 Males 143 1.0 1.4 0.18 10
Perua 2001–2005 Females 32 0.3 0.3 0.04 78 25 86 0.1 0.2 0.02 21
2001–2005 Males 146 1.6 1.7 0.19 82 19 302 0.4 0.6 0.06 15
Suriname 2003–2007 Females 2 0.2 0.2 0.01 20
2003–2007 Males 10 0.8 1.0 0.13 13
Uruguay 2005–2007 Females 44 0.9 0.5 0.06 75 24 25 0.5 0.3 0.03 21
2005–2007 Males 450 9.4 7.2 0.92 84 12 345 7.2 5.4 0.69 9
Venezuela 2003–2007 Females 252 0.4 0.5 0.05 19
2003–2007 Males 1435 2.1 3.0 0.36 7
ASR (W), age-standardized (World population) rate per 100,000; Cum, cumulative; MV, microscopic veriﬁcation.
a Incidence rates were estimated using data from regional cancer registries.
b Rank based on highest ASR excluding: All sites but C44 and All sites.
c Mortality rates based on small number of cases.
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(OR = 0.23 [0.18, 0.31] versus current smokers). Cessation of alcohol
drinking after 20 years was associated with a 40% [0.40, 0.89]
lower risk of head and neck cancers than that in current drinkers.
Quitting smoking or alcohol consumption for 20 years yielded a
relative risk similar to those who never smoked or consumed
alcohol [16]. In a previous study in Brazil, Schlecht et al. [17] found
an independent effect of alcohol cessation among current smokers,
showing a reduction of 23% in the risk of developing oral and
pharyngeal cancer (RR = 0.77 [0.3, 2.0]) for abstainers from alcohol
compared to current drinkers. These results highlight the overall
importance of the interventions that should be implemented to
reduce the high risk for HNSCC associated with both tobacco and
alcohol consumption.
Currently, four of the 25 largest tobacco producers in the world
are located in Brazil, Argentina, Cuba, and Colombia. In 2009 Brazil
produced 32% more tobacco than the entire African region, and
incremented its production by 49% between 2000 and 2009
[18–20]. For the year 2006 between 8% and 10% of the smokers of
the world lived in Latin America, and the reported smoking
prevalence for 2005 ranged between 4.1% in Guatemala and 34.8%in Cuba [19]. According to the 2015 WHO global report on trends
and projections in tobacco smoking 2000–2025 [21], the region
has shown trends of overall reduction in tobacco consumption
based on relative change in age-standardised prevalence of current
smoking between 2000 and 2010 among persons from both sexes
aged 15 years and over [22].
The WHO created the Framework Convention on Tobacco
Control (FCTC) to reduce the worldwide prevalence of smoking and
exposure to tobacco smoke by a third by 2025. The FCTC provides a
framework (legal, regulatory, and policy) to promote non-smoking
lifestyles. Currently, all countries in Central and South America
have signed or ratiﬁed the WHO FCTC with the exception of
Argentina, Cuba, and El Salvador. Ten countries adopted legislation
to ban smoking in all indoor public places and workplaces;
12 implemented regulations on the packaging and labelling of
tobacco products (only nine included a warning label message
speciﬁcally related to mouth, pharynx or larynx cancer); ten
introduced bans on tobacco advertising, promotion, and sponsor-
ship; and 12 introduced a tax share of 50% of the total price of
cigarettes [23,24]. Although most countries in the region have
implemented the WHO’s recommendations, only Brazil, El
Fig. 3. Trends in cancer incidence and mortality by country and sex, all ages.
S48 S. Perdomo et al. / Cancer Epidemiology 44S (2016) S43–S52Salvador, Panama and Uruguay have national smoking quit lines,
offer nicotine replacement therapies, and have some health system
plans to cover the cost of cessation services [25,26]. The growing
economy experienced by most countries in Central and South
America and the low prices of cigarettes (compared to those in
other regions) have incremented the affordability of tobacco
products. This is a major concern because of the high prevalence ofFig. 4. Estimated annual percentage change in age-standardtobacco consumption among adolescents in the region, in
particular Chile, Argentina, Uruguay, Cuba and Brazil.
According to the WHO (2014), in 2010 the average per capita
consumption of alcohol in the Central and South American region
was higher than that of the world average (estimated 7.3 L for those
15 years and older in both sexes compared with 6.2 L around the
world) [27]. Since 2010, the WHO’s Substance Abuse Departmentized incidence and mortality rates per 100,000 by sex.
S. Perdomo et al. / Cancer Epidemiology 44S (2016) S43–S52 S49(WHO/SAB) made the prevention and reduction of the harmful use
of alcohol a public health priority and created a global strategy to
reduce the harmful use of alcohol. In 2011, PAHO Member States
approved the Plan of Action to Reduce the Harmful Use of Alcohol
(Resolution CD51.R14). Major policy efforts to control alcohol
consumption in the region focused on countermeasures against
driving while intoxicated, actions to alter the drinking context, and
limits on alcohol availability. According to those criteria, Colombia,
Costa Rica, Venezuela, and El Salvador adopted the highest-impact
policies overall, while Brazil, Suriname, and Uruguay need the
most improvement. Even though most countries in Central and
South America have a taxation system, alcoholic beverages
continue to be very cheap as the taxes might be outdated and
not regularly adjusted with inﬂation or the index price of other
goods [28].
3.4. HPV associated cancer prevention
It has been estimated that 25.6% (22,000 cases) of the
85,000 oropharynx cancers cases occurring globally in 2008 were
due to HPV infection, including 780 cases occurring in Central and
South America alone [29]. Data on HPV prevalence in the Central
and South American region are scant, with only a few small studies
available (sample sizes ranging from 5 to <250 cases) and different
HPV detection techniques used [30]. The prevalence of HPV16 in
HNSCC ascertained by both viral DNA detection and by serum
antibodies E6 and E7 has been evaluated in three case–control
studies that included cases from Latin America (Argentina, Brazil
and Cuba) [31–33]; overall, Latin America had a lower prevalence
(between 3.1 and 3.9%) of HPV16 related HNSCCs as compared with
Europe and North America [34–36].
Primary prevention of HPV-related head and neck cancer with
HPV vaccines is still under evaluation. It is assumed that the
preventive potential of the HPV16/18 vaccine may be due to its
acting not only directly but also indirectly by reducing the
incidence of oral/oropharyngeal HPV16/18 infection through the
reduction in the prevalence of genital HPV16/18 infection. The only
study to have evaluated the efﬁcacy of the bivalent vaccine in
reducing oral HPV infection used data nested from community-
based double-blind randomized trial in Costa Rica and tested HPV
presence in oral exfoliated cells in women. The prevalence of oral
HPV16/18 infection among women in the vaccine arm was 0.03%
(1/2910) and in the control arm was 0.5% (15/2924) 4 years after
the ﬁrst vaccination dose (vaccine efﬁcacy 93.3% [62.5%, 99.7%]).
However, the study was limited to measuring the HPV prevalence
rather than the incidence of new infections 4 years after
vaccination, and using only one-time detection of oral HPV as
the end-point, not being able to discard incident HPV infection
[37,38].
3.5. Screening programs
Screening programs using oral visual inspection have been
proposed as the main strategy for secondary prevention of oral
cavity cancers. However, evidence that a visual examination as part
of a population-based screening program reduces the mortality
rate of oral cancer in high-risk individuals is limited [39,40]. A few
initiatives in Latin America have been proposed as part of national
campaigns and or screening programs: Cuba introduced an oral
cancer screening program in 1982 which was adopted by the
health services in 1984. The program was based on regional
stomatology clinics that preformed opportunistic annual oral
inspection of subjects age 15 years and over in the assigned
population of 1000–1200 patients. A matched case–control study
in 2002 evaluated the efﬁcacy of this program and showed that the
odds of having advanced oral cancer (stage III and IV) 3 monthsprior to the cancer diagnosis was 33% [46%, 95%] lower in cases
than in controls, indicating that oral visual inspection resulted in
protection from a diagnosis of advanced oral cancer [41].
In Brazil several initiatives to develop head and neck cancer
prevention programs have been proposed to include opportunistic
oral examination among the population at risk. In 1974 the
Ministry of Health in collaboration with the Brazilian Society of
Stomatology (SOBEP) introduced an oral cancer prevention
program and 10 years later, the “Programa de Expansão da
Prevenção e Controle do Câncer da Boca (PEPCCB)” was launched as
part of the national campaign against cancer. In 2011, the Ministry
of Health implemented a National Program for Improving Access to
and Quality of Primary Health Care which included oral mucosal
changes in the list of oral health markers, encouraging dentists to
search for oral lesions and consequently promoting early cancer
diagnosis [42]. A few investigators have tried to evaluate the
efﬁcacy of those programs, although none have investigated
staging shift or reduction in mortality rates [43,44].
4. Discussion
The present results highlight the variability of HNSCC incidence
and mortality rates across countries in the Central and South
America region, with Brazil, Cuba, Uruguay and Argentina
experiencing the highest rates. Brazil has the highest incidence
rates of oral and pharyngeal cancer in the region for both sexes and
the second highest ASR for males in the developing world [45].
Consistent with the ﬁndings presented by Bosetti et al. and
Chatenou et al. [5,46], mortality due to this malignancy in Brazil is
on the rise in both males and females; however, none of the
estimates were statistically signiﬁcant. Therefore, further moni-
toring of these cancers is necessary in order to identify statistically
signiﬁcant changes over time.
Comparison of the data available for two different periods in
Costa Rica (1985–1989 and 2003–2007) showed a reduction in
incidence rates in both sexes and a notable decline in four positions
in the national rank of cancer incidence; this might reﬂect to some
extent the effect of anti-tobacco policies implemented in the
country in the early 1990s [47].
Mortality rates for the region have experienced a leveling as
reported by Chatenoud et al. [5] in Argentina, Chile, Colombia,
Costa Rica, Cuba Ecuador, Mexico and Uruguay over a 20-year
period; these are similar to mortality rates in western European
countries and the US [2].
Cuba had the highest age-standardized incidence rates (per
100,000) of laryngeal cancer in males and females, reﬂecting the
widespread smoking pattern of the Cuban population (prevalence
of smoking in 2015: 52.7 [23.7–91.0] in men and 17.8 [7.5–31.8] in
women) [48]. On the other hand, Peru has one of the lowest
incidence rates in the region which could reﬂect the important
decline in the smoking prevalence (9.7[6.3–13.2]in 2000–5.9 [4.4–
7.7] in 2015 for females) [48]. Walter et al. [49] reported an annual
percentage change (age-adjusted) of 0.9 [95% conﬁdence
interval, 2.3, 0.6] for laryngeal cancer incidence in Lima from
1987 to 2008.
Declines in mortality rates of laryngeal cancers of similar or
larger magnitudes have been reported among males in Argentina
(estimated annual change of 1.72 for 1990–2005) [50] and Chile
(–34.77% from 1.79 to 1.17 per 100,000 1990–2004) [51]. According
to the last results from the EUROCARE-5 study the European mean
age-standardized 5-year relative survival for laryngeal cancer in
both sexes is 55% [52]. It has been suggested that differences in
prognosis for speciﬁc anatomical subsites (supraglottis and glottis)
may account for some of the variation in the estimated survival
[53]. Additional factors that might account for the observed
variations in cancer survival across different populations include:
S50 S. Perdomo et al. / Cancer Epidemiology 44S (2016) S43–S52the clinical spread of disease, which for developing country
populations is mostly related to a high proportion of locally
advanced disease, and disparities in access to diagnosis and
treatment.
Overall incidence and mortality rates for HNSCC reveal an
important and alarming situation with regard to smoking and
drinking behavior in the Central and South American region, which
conveys the need to develop anti-smoking interventions and
supports abstention or moderation in alcohol drinking. Improve-
ment and implementation of comprehensive tobacco and alcohol
control policies as well as monitoring of these factors are
fundamental to prevent head and neck cancers in the region,
particularly for countries with high tobacco prevalence and alcohol
consumption such as Argentina, Brazil, Cuba, and Uruguay which
have the highest head and neck cancer incidence and mortality
rates in the region. These comprehensive approaches should be
guided by the implementation of the WHO’s recommendations
(taxation, age limits, and availability restriction) as well as
education to the public (including the youth) about the dangers
of smoking and alcohol consumption and responsible drinking
(including those serving alcoholic beverages), taking into account
the regional culture. In general, the drinking pattern of Central and
South America is characterized by high alcohol intake per occasion,
ﬁesta drinking, drinking in public places, and not drinking with
meals (this last one excluding high wine-consuming countries)
[54]. This could perhaps be achieved through a strategy that
combines early intervention for problem drinkers in healthcare
settings and cost-effective interventions (following the WHO’s
recommendations mentioned above) [25,26].
There is still limited knowledge about the natural history of HPV
oral infection and time of oropharyngeal cancer development.
Thus additional studies need to further explore whether HPV
vaccines prevent HPV infection and ultimately HPV-related head
and neck cancers, and to deﬁne the potential cost–beneﬁt of HPV
vaccines in the prevention of these cancers.
In 2007 the World Health Assembly WHO passed a resolution
adopted by the Global Oral Health Program emphasizing the need
to include prevention of oral cancer as an integral part of national
cancer control programs and to involve oral health professionals or
primary healthcare personnel with relevant training in oral health
in detection, early diagnosis and treatment [55,56]. Even though
there have been some early attempts to implement screening
programs in the region, the most frequently reported weaknesses
of the programs are related to difﬁculties in implementing a
network for the diagnosis of oral cancer, such as: absence of
integration between primary, secondary, and tertiary oral health
care centers; lack of knowledge and experience from primary care
dentists to identify malignant lesions or perform biopsies; and
difﬁculties reaching the population at risk [43,44]. Therefore,
public awareness of early symptoms as well as healthcare
providers’ education should allow early detection and decrease
treatment-related morbidity.
The present study has several strengths and limitations. We
aimed to describe the current burden of head and neck cancer in
Central and South America and included the most readily available
incidence data from 13 countries (48 cancer registries), more than
the data published in the latest volume of Cancer Incidence in Five
Continents (eight countries, 22 cancer registries) [57] and national
mortality data from 18 countries. However, data patterns must be
interpreted with caution because for most countries nationwide
incidence rates are represented by aggregated data from regional
registries which do not cover the entire country (except for Costa
Rica and Uruguay). Registrations may also differ in completeness
and data quality which depend on the maturity of the cancer
registry. In Mexico and Bolivia 100% of the head and neck cancer
cases were microscopically veriﬁed (MV, Tables 2 and 3) indicatingan over-reliance on the pathology laboratory as a source of
information and probably missing other sources of information
[58,59].
5. Conclusion
HNSCC incidence and mortality rates in the Central and South
America region vary considerably across countries, with Argentina,
Brazil, Cuba, French Guyana and Uruguay experiencing the highest
rates in the region. Brazil had the highest incidence and mortality
rates of oral cavity and pharyngeal cancer in the region for both
sexes followed by Uruguay and Cuba. Cuba had the highest
incidence and mortality rates of laryngeal cancer of any other
country in the region, for both males and females, followed by
Brazil, Uruguay and Argentina. Males had consistently higher rates
of these cancers than females. Available time trends for Argentina,
Brazil, Chile and Costa Rica showed no statistically signiﬁcant
variations over the most recent 10 years. Geographic variation and
sex disparity may be explained by different etiologies of these
disease entities and by the distribution of risk factors in the region.
Tobacco smoking and alcohol use are the main risk factors
consistently associated with the incidence and mortality of head
and neck cancers. Most countries in the region have implemented
WHO recommendations to establish public policies for both
tobacco and alcohol control. Consequently, these policies are likely
to reduce the incidence and mortality of head and neck cancers in
the future. There is a persistent high per capita alcohol consump-
tion in many Central and South American countries, thus
reinforcing the necessity for more aggressive policies at the
population level (media campaigns, tobacco pricing, cessation
programs, alcohol taxation and availability restrictions), at the
community level (education prevention, smoke-free places), as
well as at the health-provider level (counselling, quit lines,
nicotine replacement patches, early intervention for problem
drinkers in healthcare settings).
HPV is strongly related to oropharyngeal tumors; however, the
reported prevalence of HPV-related tumors in Central and South
America is very low compared to that in other regions. Primary
prevention of HPV-related head and neck cancer with HPV
vaccines is still under evaluation.
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